Background
The epidermal growth factor receptor (EGFR) signaling pathway is crucial for regulating tumorigenesis and cell survival and may be important in the development and progression of non-small cell lung cancer (NSCLC). We examined the impact of EGFR-tyrosine kinase inhibitors (TKIs) on progression-free survival (PFS) and overall survival (OS) in advanced NSCLC patients with and without EGFR mutations.
Methods
Randomized trials that compared EGFR-TKIs monotherapy or combination EGFR-TKIs-chemotherapy with chemotherapy or placebo were included. We used published hazard ratios (HRs), if available, or derived treatment estimates from other survival data. Pooled estimates of treatment efficacy of EGFR-TKIs for the EGFR mutationpositive (EGFRmut + ) and EGFR mutation-negative (EGFRmut -) subgroups were calculated with the fixed-effects inverse variance weighted method. All statistical tests were two-sided.
Results
We included 23 eligible trials (13 front-line, 7 second-line, 3 maintenance; n = 14 570). EGFR mutation status was known in 31% of patients. EGFR-TKIs treatment prolonged PFS in EGFRmut + patients, and EGFR mutation was predictive of PFS in all settings: The front-line hazard ratio for EGFRmut + was 0.43 (95% confidence interval [CI] = 0.38 to 0.49; P < .001), and the front-line hazard ratio for EGFRmut -was 1.06 (95% CI = 0.94 to 1.19; P = .35; P interaction < .001). The second-line hazard ratio for EGFRmut + was 0.34 (95% CI = 0.20 to 0.60; P < .001), and the second-line hazard ratio for EGFRmut -was 1.23 (95% CI = 1.05 to 1.46; P = .01; P interaction < .001). The maintenance hazard ratio for EGFRmut + was 0.15 (95% CI = 0.08 to 0.27; P < .001), and the maintenance hazard ratio for EGFRmut -was 0.81 (95% CI = 0.68 to 0.97; P = .02; P interaction < .001). EGFR-TKIs treatment had no impact on OS for EGFRmut + and EGFRmut -patients.
Conclusions
EGFR-TKIs therapy statistically significantly delays disease progression in EGFRmut + patients but has no demonstrable impact on OS. EGFR mutation is a predictive biomarker of PFS benefit with EGFR-TKIs treatment in all settings. These findings support EGFR mutation assessment before initiation of treatment. EGFR-TKIs should be considered as front-line therapy in EGFRmut + advanced NSCLC patients.
J Natl Cancer Inst;2013;105:595-605
The greatest changes in the treatment of advanced non-small cell lung cancer (NSCLC) have been novel molecular-targeted agents and the concomitant ability to personalize treatment. Controversy continues in many areas related to the incorporation of these changes into clinical medicine. How should such therapy be selected for individual patients? Is molecular testing required or is the use of demographic factors (such as histologic NSCLC type, sex, smoking history) sufficient for personalizing therapy? Questions remain concerning whether therapy with chemotherapy or with agents affecting the epidermal growth factor receptor (EGFR) influence progression-free survival (PFS) and/or overall survival (OS) in patients who do or do not harbor known mutations associated with EGFR. Is PFS a good surrogate for OS, or is PFS a useful endpoint on its own? Data directed at answering these controversies can guide oncologists in interpreting trials and in making more appropriate diagnostic and therapeutic choices for hundreds of thousands of patients each year. The objective of this meta-analysis is to estimate better the treatment effect of EGFR-tyrosine kinase inhibitors (TKIs) on PFS and OS while examining for heterogeneity of treatment effects between groups of patients with and without EGFR mutations. The EGFR signaling pathway is crucial for regulating tumorigenesis and cell survival and may be overexpressed in the development and progression of NSCLC (1) (2) (3) . Patients with activating somatic mutations in the region of the EGFR gene that encodes the tyrosine kinase domain are highly responsive to EGFR-TKIs (4-6). Previously published meta-analyses have been limited by studying the minority of patients with NSCLC-that is, the influence of EGFR-TKIs only in the population of patients harboring EGFR mutations and predominantly in the front-line treatment setting (7) (8) (9) . These meta-analyses have not demonstrated an OS advantage for patients with EGFR mutation treated with EGFR-TKIs. This analysis uses all trial data available to date and examines the effect of EGFR-TKIs treatment in major clinical settings-front-line, maintenance, and second-line or subsequent therapies. Additionally, the impact of EGFR-TKIs-chemotherapy combinations compared with EGFR-TKIs monotherapy is also explored. It is now recognized that as with EGFR mutations, other genetic alterations [such as EML-ALK abnormalities (10) and ROS-1 mutations (11) ] are also more common in nonsmokers with adenocarcinoma, but these latter groups do not benefit from EGFR-TKIs-directed therapy. Such findings highlight the need for more specific molecular testing of patients and the need to include the most recent data from metaanalyses to understand better the treatment effects.
Individual trials and meta-analyses have clearly indicated that PFS and response rates are improved in patients with EGFR mutation who are treated with EGFR-TKIs, when compared with chemotherapy (7) (8) (9) . The impact on OS is less clear, especially in patients treated beyond first-line therapy. Two separate trials have indicated that erlotinib is effective as second-line (12) and maintenance (13) therapy, with no statistically significant difference in treatment effect between those with EGFR mutation and wild-type tumors. However, a recent trial reported that chemotherapy was superior over erlotinib as second-line treatment for patients without EGFR mutations in exon 19 or 21 (14) . Clearly, newer and larger meta-analyses are required to resolve these differences. Definitive analyses can provide stronger rationales for the choice of a specific therapy and can result in better utilization of health-care resources with these costly agents. For these reasons, we conducted this meta-analysis, which included the largest number of studies and patients to date with known EGFR mutation status and tested both PFS and OS as outcomes.
Methods

Study Eligibility and Identification
All randomized trials of EGFR-TKIs monotherapy vs any chemotherapy, EGFR-TKIs and chemotherapy vs the same chemotherapy alone, and EGFR-TKIs monotherapy vs placebo or best supportive care were eligible for inclusion.
Trials were identified from previous meta-analyses (7) (8) (9) , and a search of Medline, Embase, CancerLit, and the Cochrane Central Register of Controlled Trials (CENTRAL) using the following terms: lung neoplasms, non-small cell lung cancer, gefitinib, erlotinib, EGFR, meta-analysis, systemic review, randomized, and clinical trials. Database searches were restricted to articles published in the English language between January 1, 2004, and June 6, 2012. Trials that enrolled patients with prior EGFR-TKIs treatment were excluded. Abstracts from conference proceedings of the American Society of Clinical Oncology, the European Society for Medical Oncology, and the World Lung Cancer Conference were searched to identify unpublished studies. Individual study sponsors (Hoffmann-La Roche and AstraZeneca) were contacted for relevant presentation slides and posters from these conferences when they were inaccessible from the websites. Individual investigators were also contacted if essential information relevant to this metaanalysis was unavailable from these sources.
Data Extraction
Information recorded from each trial included study name, year of publication or conference presentation, study design, line of treatment, and clinicopathological and demographic data. Mutational analysis data were also extracted, and the different methods of EGFR mutation assessment were recorded. We classified patients as EGFR mutation-positive (EGFRmut + ) based on the presence of a mutation as detected using molecular assessment tools such as Sanger sequencing, polymerase chain reaction clamp, and amplification refractory mutation system. Patients were classified as EGFR mutation-negative (EGFRmut -) if no mutation was detected. We did not classify patients' EGFR mutation status based on immunohistochemistry and fluorescent in situ hybridization for EGFR gene copy numbers. Most trials analyzed exons 19 and 21 for EGFR mutations, and some trials also included exons 18 and 20.
Data were extracted independently by three authors (J. C.-H. Yang, C. K. Lee, and C. Brown), and discrepancies were resolved by consensus including a fourth author (V. Gebski).
Statistical Analyses
We extracted the hazard ratios (HRs) and the associated 95% confidence intervals (CIs) for PFS and OS outcomes to assess treatment efficacy within the EGFRmut + and EGFRmut -subgroups. Where available, we included the most updated OS data. If hazard ratios and confidence intervals were not reported, these were estimated where possible using the methods of Parmar (15) .
Pooled estimates of the treatment efficacy of EGFR-TKIs for the EGFRmut + and EGFRmut -subgroups were calculated by using the fixed-effects inverse variance weighted method. We performed indirect comparisons to quantify the benefits of adding chemotherapy to EGFR-TKIs over EGFR-TKIs alone in both subgroups.
A sensitivity analysis was also conducted to examine the impact of the overall results from this study by limiting the analyses on front-line trials that were known to have determined EGFR mutation based on exons 19 and 21 only.
We used the χ2 Cochran Q test to detect for heterogeneity across the different studies and between subgroups defined by EGFR mutation status, study setting, and study design. The nominal level of significance was set at 5%. All 95% confidence intervals were two-sided.
Cochrane Review Manager (version 5, Cochrane Collaboration, Copenhagen, Denmark, http://ims.cochrane.org/home) was used for all analyses.
Results
The search strategy identified 40 studies, of which 23 (12) (13) (14) were eligible for inclusion in this meta-analysis ( Figure 1 ). Trial data were obtained from published manuscripts and conference abstracts for 19 trials, and additional data on treatment efficacy by EGFRmut + and EGFRmut -subgroups were obtained directly from study investigators for four studies [ISEL (41), V-15-32 (31), TOPICAL (43) , and IFCT-GFPC 0502 (32, 44) ]. Treatment estimates for the TALENT study (37) were calculated on the basis of data extracted from presented survival curves. The hazard ratios for OS for ISEL (41) , IFCT-GFPC 0502 (32, 44) , and V-15-32 (31) were estimated on the basis of the observed number of deaths. In all other studies, hazard ratios and associated variances were obtained directly from trial reports.
A total of 14 570 patients participated in these 23 trials. EGFR mutation status, as determined by mutation analysis only, was known for at least 31% (n = 4473) of trial patients. [In the TALENT study (37) , the treatment comparisons for the subgroups were reported, but the number of patients in each subgroup was unknown.] Clinicopathological and demographic characteristics of patients enrolled in these studies are summarized in Table 1 .
Trials investigated EGFR-TKIs for front-line therapy in treatment-naive patients (n = 13 trials), second-line or subsequent treatment after failure of chemotherapy (n = 7 trials), and maintenance treatment in patients with nonprogressive disease after front-line chemotherapy (n = 3 trials). Among the 13 front-line studies, eight compared EGFR-TKIs as monotherapy vs chemotherapy (16) (17) (18) (19) (20) (21) 23, 27, (33) (34) (35) 38) , four compared EGFR-TKIs with chemotherapy vs chemotherapy alone (22, (24) (25) (26) 37, 45) , and one was a placebo-controlled trial (36, 43) . Among the seven secondline and subsequent treatment trials, five compared EGFR-TKIs as monotherapy vs chemotherapy (12, 14, 28, 29, 31, 42) , and two were placebo-controlled studies (39) (40) (41) . All three maintenance studies had a placebo arm (13, 30, 32, 44) .
Benefit of EGFR-TKIs on PFS in Different Settings
Data on PFS were available from 21 trials except ISEL (41) and BR21 (39) . The treatment effect of EGFR-TKIs in different settings is shown in Figure 2 . The test of interaction between treatment and EGFR mutation status was statistically significant (front-line setting: P < .001; second-line or subsequent treatment: P < .001).
In EGFRmut + patients, EGFR-TKIs treatment was associated with a lower risk of disease progression in the front-line setting (HR = 0.43; 95% CI = 0.38 to 0.49; P < .001) and second-line or subsequent treatment (HR = 0.34; 95% CI = 0.20 to 0.60; P < .001).
In EGFRmut -patients, EGFR-TKIs did not show a treatment advantage in the front-line setting or beyond. There was no statistically significant difference between EGFR-TKIs and chemotherapy in reducing the risk of disease progression in front-line therapy (HR = 1.06; 95% CI = 0.94 to 1.19; P = .35). EGFR-TKIs treatment was statistically significantly inferior to chemotherapy in second-line or subsequent therapy (HR = 1.23; 95% CI = 1.05 to 1.46; P = .01).
Maintenance therapy with EGFR-TKIs compared with placebo was effective in reducing the risk of disease progression in EGFRmut 198 (18) 851 ( and EGFRmut -subgroups (EGFRmut + : HR = 0.15, 95% CI = 0.08 to 0.27, P < .001; EGFRmut -: HR = 0.81, 95% CI = 0.68 to 0.97, P = .02). The test of interaction between treatment and EGFR mutation status was statistically significant (P < .001).
Effect of EGFR-TKIs Combined With Chemotherapy on PFS
Data were available for four trials [INTACT 1 and 2 (45), TRIBUTE (22) and TALENT (37) ] that combined EGFR-TKIs with chemotherapy. Combination EGFR-TKIs and chemotherapy compared with chemotherapy alone was effective in reducing the risk of disease progression in both subgroups (EGFRmut + : HR = 0.54, 95% CI = 0.30 to 0.95, P = .04; EGFRmut -: HR = 0.82, 95% CI = 0.68 to 0.98, P = .03; treatment-by-EGFR mutation status interaction: P = .17) (Figure 3) . When EGFR-TKIs monotherapy was compared with chemotherapy, EGFR-TKIs treatment was associated with a reduced risk of disease progression in the EGFRmut + subgroup (HR = 0.42; 95% CI = 0.37 to 0.48; P < .001) but an increased risk in the EGFRmut -subgroup (HR = 1.56; 95% CI = 1.36 to 1.80; P < .001).
Within the EGFRmut + subgroup, an indirect comparison of data available from these trials indicates EGFR-TKIs treatment in combination with chemotherapy was not more effective than EGFR-TKIs alone in reducing the risk of disease progression (HR = 1.42; 95% CI = 0.80 to 2.53; P = .23). By contrast, within the EGFRmut -subgroup, EGFR-TKIs treatment in combination with chemotherapy was more effective in reducing the risk of disease progression than EGFR-TKIs alone (HR = 0.51; 95% CI = 0.43 to 0.62; P < .001).
Effect of EGFR-TKIs on OS in Different Settings
Data on OS were available from 19 trials except Lux Lung 3 (34), TAILOR (14) , KCSG-LU08-01 (42), and INFORM (30) . Subgroup analyses by treatment setting are summarized in Figure 4 . The test interaction for treatment and EGFR mutation status was not statistically significant (front-line setting: P = .91; second-line or subsequent therapy: P = .37). For EGFRmut + patients, there was no treatment advantage of EGFR-TKIs in the front-line setting (HR = 1.01; 95% CI = 0.87 to 1.18; P = .86) or for second-line or subsequent therapy (HR = 0.74; 95% CI = 0.45 to 1.19; P = .21) in the risk of death. Similar results were observed in EGFRmut -patients. Only two studies [SATURN (13) and IFCT-GFPC 0502 (32, 44) ] reported OS in the maintenance setting. There was no clear benefit of treatment with EGFR-TKIs over placebo in either EGFRmut + patients (HR = 0.78; 95% CI = 0.33 to 1.84; P = .57) or EGFRmut -patients (HR = 0.84; 95% CI = 0.69 to 1.04; P = .10). The test for interaction between treatment and EGFR mutation status was not statistically significant (P = .87).
Publication Bias
In this meta-analysis, the overall treatment effect was not statistically significant for the OS outcome. Any potential publication bias through the exclusion of non-statistically significant studies would therefore not have influenced these results.
Sensitivity Analysis
EGFR mutation, based on exons 19 and 21 only, was known to have been examined in three trials in a front-line setting (Table 1) . One trial (34) provided the treatment estimate for PFS limited to patients with exons 19 and 21 only. In the front-line setting, similar qualitative results were obtained when the analyses were limited to only these four trials on PFS and OS outcomes for the EGFRmut + subgroup ( Supplementary Figures 1 and 2 , available online).
Discussion
This study extends the analysis beyond prior publications of the most clinically important molecular factor relevant to the treatment of NSCLC. Increased confidence in the findings is evident through the incorporation of results from 23 trials in nearly 15 000 patients with more than 4000 having molecular analysis. Additionally, this study approached issues not addressed in prior meta-analyses. As such, results from this study have implications for treatment and for study interpretation and design.
This meta-analysis summarizes the best available evidence to guide the use of EGFR-TKIs in patients with advanced NSCLC. EGFR-TKIs treatment is associated with 57% and 66% reduction in the risk of disease progression in EGFRmut + patients in frontline and second-line settings, respectively, but with no benefit in EGFRmut -patients (Figure 2 ). This study also demonstrates that EGFR mutation is an important predictive biomarker of TKIs treatment benefit in terms of PFS for all settings: front-line, maintenance, and second-line or subsequent therapy. This study demonstrates for the first time that the magnitude of effect on PFS for EGFRmut + patients is similar in patients receiving EGFR-TKIs in either the first-or second-line setting (HR = 0.43 and 0.34, respectively).
Even with mutational analyses in more than 4000 patients and with a large PFS benefit, this meta-analysis does not demonstrate OS advantage with EGFR-TKIs. Regardless of EGFR mutation status, the overall treatment effects on OS were similar. The frequently suggested reason for this lack of OS effect is the confounding effect of postprogression therapy between the randomization arms. None of the front-line trials prohibited patients from crossing over to the other treatment arm, and crossover was increasingly frequent over the decade during which these trials were conducted. For example, the NEJ002 trial randomly assigned patients to receive either gefitinib or chemotherapy. Not only did most patients receive subsequent treatment, but 94.6% of patients in the chemotherapy arm were reported to have received second-line gefitinib on disease progression (17) . A recent systematic review of chemotherapy trials also indicated that PFS advantage is unlikely to be associated with an OS advantage with increasing impact of salvage therapy and that the prolongation of survival postprogression might limit the role of OS for assessing true efficacy derived from front-line therapy (46) . Moreover, analysis of a recent trial indicated that compared with EGFRmut -patients, twice as many EGFRmut + patients responded to chemotherapy (28) . Crossover effects, lack of blinding in experimental arms, and other factors that have been previously discussed can make PFS a difficult surrogate for OS (47) (48) (49) . Ongoing work is still required to demonstrate the impact of other clinically meaningful benefits of EGFR-TKIs beyond survival and PFS for these patients.
Controversy continues regarding the role of the addition of EGFR-TKIs in patients receiving chemotherapy. For this reason, we analyzed this issue in four large, published, prospective, randomized trials in front-line treatment [INTACT 1 and 2 (45), TALENT (37) , and TRIBUTE (22)]. Pooled results from these four front-line trials showed that combining EGFR-TKIs with chemotherapy over chemotherapy alone statistically significantly delayed disease progression in both the EGFRmut + and EGFRmut -subgroups. Preclinical studies (50, 51) have demonstrated a synergistic effect of combining EGFR-TKIs with chemotherapy. However, indirect comparison of trial arms suggests that combined EGFR-TKIs treatment and chemotherapy is not more effective than EGFR-TKIs alone in reducing the risk of disease progression in EGFRmut + patients (HR = 1.42; 95% CI = 0.80 to 2.53; P = .23). A lack of additional benefit was confirmed in a prospective phase II trial (52) in which erlotinib monotherapy was compared with erlotinib chemotherapy combination in the EGFRmut + subgroup (median PFS 14.1 vs 17.2 months).
This meta-analysis provides information to define better the relative effectiveness of EGFR-TKIs for EGFRmut -patients. In front-line therapy, there was a non-statistically significant difference between EGFR-TKIs and control in reducing the risk of disease progression (pooled HR = 1.06; P = .35). This finding is consistent with previous in vitro studies that demonstrated a lack of sensitivity of wild-type EGFRmut -receptor lung tumor to EGFRTKIs treatment (4) (5) (6) . Although a small benefit of EGFR-TKIs over placebo in the EGFRmut -subgroup has been demonstrated in three maintenance studies [SATURN (13) , INFORM (30) , and IFCT-GFPC 0502 (32, 44) ] (pooled HR = 0.81; 95% CI = 0.68 to 0.97; P = .02), it must be realized that this benefit is markedly and both clinically and statistically significantly greater in EGFRmut + subgroups (pooled HR = 0.15; 95% CI = 0.08 to 0.27; P < .001), and the test of interaction between EGFR mutation status and treatment is highly statistically significant (P < .001).
This meta-analysis also examined the role of EGFR mutation in selecting patients for second-line or subsequent treatment. A 2012 editorial has illustrated the debate in this area (53) . Although trials have differed in their results, one study (TAILOR) reported that chemotherapy was statistically significantly superior over erlotinib in terms of tumor response and PFS (OS results are not yet available) in patients without EGFR mutations in exon 19 or 21 undergoing second-line treatment, but the data remain premature and only available as a conference presentation (14) . In the current meta-analysis, pooled results from trials of second-line and subsequent therapies demonstrated that treatment with EGFR-TKIs treatment, compared with chemotherapy, was associated with a 66% reduction in the risk of disease progression in the EGFRmut + subgroup (Figure 2 ). In contrast, EGFR-TKIs treatment, compared with chemotherapy, was 23% inferior (Figure 2 ) in delaying disease progression (but not OS) in EGFRmut -patients with good performance status who were suitable to receive chemotherapy. The test of interaction between EGFR mutation status and second-line or subsequent treatment was statistically significant (P < .001), suggesting that EGFR mutation is still an important treatment effect modifier and should be used to guide treatment decisions in this setting. Interestingly, updated results from the TOPICAL trial demonstrated that rash during the first cycle predicted PFS benefits with erlotinib in the EGFRmut -subgroup (43) . This meta-analysis has several strengths. We performed a comprehensive review, reported the most up-to-date published data, and contacted individual investigators to obtain relevant unpublished data. By examining both the EGFRmut + and EGFRmut -subgroups, the value of EGFR mutation status as a treatment effect modifier can be adequately assessed. This meta-analysis also overcomes the problem of inadequate power of individual studies to compare subgroups. For example, only six studies (16, 18, 19, 21, 34, 38) included in this review had EGFRmut + results for more than 50 patients. Reliable interpretation of independent treatment effects in most of the individual studies in this review is not possible because of small sample sizes. Altogether, more than 4000 patients with mutational analysis were included in this study. A major strength of this current meta-analysis is that the pooled results allow examination of second-line and maintenance treatment as well as elucidation of the effect of adding EGFR-TKIs to chemotherapy.
There are also limitations that should be noted from this analysis. Firstly, we assumed that all EGFR-TKIs, including gefitinib, erlotinib, and afatinib, have equivalent therapeutic efficacy for both the EGFRmut + and EGFRmut -subgroups. Secondly, EGFR mutation status was only assessed in 31% of patients enrolled in eligible trials, with treatment efficacy estimated from small numbers of EGFRmut + patients identified in many of these trials ( Table 1 ). The potential influence on the results of restricting our analyses to this subset of patients is unknown. We further obtained efficacy data in the subgroups with known EGFR mutation status through personal communication with investigators of four trials (31, 32, 41, 43) . Although these subgroup data have not been published, the primary trial outcomes of these studies have been peer reviewed. Although nearly 15 000 patients were included in the analysis, the fact that only a minority had reported mutational analysis limits the ability to address several issues. Sequencing was the most commonly used method to detect EGFR mutation, and it has poor sensitivity in detecting EGFR mutant alleles in DNA samples extracted from tumors (54) . These DNA samples may contain both malignant and nonmalignant (from adjacent normal or tumor stroma) cells and hence may impact the outcome of this meta-analysis through misclassification of patients' EGFR mutation status. Moreover, mutation of EGFR exons 19 and 21 are sensitizing mutations predictive of PFS benefit with EGFR-TKIs, whereas de novo mutations in exon 20 might reduce the effectiveness of EGFR-TKIs (55) (56) (57) . In this meta-analysis, patients classified as EGFRmut + in some trials included those with mutations in exon 20. However, when we restricted our analysis to studies that classified patients as EGFRmut + based on presence of EGFR exon 19 and exon 21 mutations, we observed similar quantitative results. In front-line therapy, information on crossover and postprogression therapies was often not available, so adjustments could not be made to account for the lack of OS benefit in EGFRmut + patients treated with EGFR-TKIs. Many reports have confirmed that EGFR mutations are more commonly found in patients with adenocarcinoma and in patients with low-and never-smoking histories. These factors have led to the debate as to whether knowledge of such demographic factors, rather than use of molecular studies, would be sufficient for treatment. The current meta-analysis, which examines multiple treatment settings, demonstrates that EGFR mutation status should guide personalization of treatment. Additionally, recent findings have reported that these same demographic features are more common in other genetic differences [such as those associated with EML-ALK translocations (10) and ROS 1 mutations (11)] that are not beneficially affected by EGFR-TKIs and for which specific therapy is available. Determining mutational status can avoid side effects of either EGFR-TKIs or chemotherapy and can lead to rational decision making. In that only the minority of all patients with NSCLC will have EGFR or other treatment-altering mutations, and because nearly all lung cancer therapy is costly, molecular analysis is increasingly important from clinical, scientific, and economic perspectives.
In conclusion, based on this meta-analysis, treatment with EGFR-TKIs statistically significantly delays disease progression in EGFRmut + patients but has no demonstrable impact on OS. EGFR mutation is a predictive biomarker of benefit with EGFR-TKIs treatment in delaying disease progression in front-line, secondline, and subsequent therapy and in maintenance settings. These findings support assessment of EGFR mutation status before initiation of EGFR-TKIs treatment and indicate that EGFR-TKIs should be considered as front-line therapy in EGFRmut + patients with advanced NSCLC.
